Retension Pharmaceuticals, Inc. (RTSN)
10.67
-0.05
(-0.47%)
USD |
NASDAQ |
Nov 06, 10:09
Retension Pharmaceuticals Debt to Equity Ratio : -1.888 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.888 |
| Date | Value |
|---|---|
| March 31, 2026 | -2.134 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| AbbVie, Inc. | -17.65 |
| Abeona Therapeutics, Inc. | 0.1552 |
| America Great Health | -0.6512 |
| Acumen Pharmaceuticals, Inc. | 0.7602 |
| Aardvark Therapeutics, Inc. | 0.0091 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 16.13M |
| Total Liabilities (Quarterly) | 31.05M |
| Shareholders Equity (Quarterly) | -14.92M |
| Current Ratio | 5.609 |